Recent News
Read ArticleA retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk.
2026 Resolutions (1.9.2026)
Dr. Cush reviews the news, announcements and journal articles from this past week on RheumNow. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
https://t.co/DgY2trZGKA https://t.co/3ka4SDRnJO
Dr. John Cush @RheumNow ( View Tweet)
US News & World Report - Top 10 jobs in the USA (growth, pay, security); the only HCP listings:
#5: Physician Assistant: Median salary: $133,260; Unemployment 1.6%; 33,100 new jobs by 2034
#1: Nurse Practitioner: Median salary: $129,210; Unemployment 0.6%; 128,400 new jobs by https://t.co/5c2hVc4ooi
Dr. John Cush @RheumNow ( View Tweet)
Nursing Shortage Could Worsen Due to Limited Student Loans
MedPage Today
In November, we reported on nursing groups that pushed back against a Trump administration proposal to de-list nursing as a professional degree for purposes of student borrowing. In this report, we look ahead to see what might happen as a result of the policy change.
Read Article
Geisinger. Medical Center (PA) has medical staff of nearly 1,800 and another 1,200 advanced practice providers (NPs, PAs, CRNAs, midwives). They offer specialized training (eg Advanced Practitioner Fellowship in Critical Care Medicine ) and have an Advanced Practice Nursing https://t.co/pCaPWe6niB
Dr. John Cush @RheumNow ( View Tweet)
1 in 3 NPs and PAs switch specialties at least once in career; often without formal training in the specialty. Both "depend on MDs for mentorship and training". Hence AMA is opposed to Removing physician supervision or collaboration requirements” for nonphysician providers https://t.co/8RXL8zre0p
Dr. John Cush @RheumNow ( View Tweet)
A 2 yr. old female pt reported w/ a a novel P435S gain-of-function variant in TLR7 (thought pathogenic in SLE) - pt dx w/ juvenile SLE, recurrent infection, and neuroinflammatory features. A review of 12 other TLR7 GOF variants revealed similar SLE associations. https://t.co/TGgKDQ0D7F
Dr. John Cush @RheumNow ( View Tweet)
EasyJIA score - a tool developed to refer juvenile pts w/ MSK sxs for rheum referral. 342 pts, (18%) Dx w/ JIA. 8 variables (10 total points) includes large Jts, daily Sxs, JT swelling, activity precipitating, +squeeze test, bending IP Jts, limping/stiffness, SI Pain. You need 3 https://t.co/zcCRUkuqh8
Dr. John Cush @RheumNow ( View Tweet)
ADJUST trial (248 JIA pts w/ Uveitis & inactive >6mos, either continued or weaned off adalimumab. ADA weaning resulted in more flares (68% vs 14%, mostly uveitis) w/ no protection from background DMARD Rx. Restarting ADA was mostly effective. https://t.co/ZWHfPl2UNl https://t.co/xodyrbaQOj
Dr. John Cush @RheumNow ( View Tweet)
2025 Lancet review https://t.co/Qbwup6QxZK of Osteoarthritis did not mention/endorse Rx w/ platelet rich plasma (PRP) prompting several letters of protest. Read the authors response: Despite the popularity of PRP, there are few PBO controlled high quality studies to prove its https://t.co/7pCZV9CHfJ
Links:
Dr. John Cush @RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE
Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab.
Read Article
NJ Senate (Senate Bill No. 3560) has voted to permite Physician Assistans to enter the Interstate Physician Assistant Licensure Compact, designed to streamline PA licensing to work in multiple states https://t.co/VE1DdWuFwM https://t.co/szJzShVAaz
Links:
Dr. John Cush @RheumNow ( View Tweet)
FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/OOctcfI1sT
Dr. John Cush @RheumNow ( View Tweet)
Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 75 and ACR 20) observed at APR 30 mg or 20 mg bid (RR > 2) & both doses did not affect CRP levels. GI side effx most common (see figure) https://t.co/YqfaWPvmTm https://t.co/z8PfJqp0CJ
Links:
Dr. John Cush @RheumNow ( View Tweet)
DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: Tophi Tales: Management of Uncontrolled Gout
Daric Mueller, PA-C and Andrew Sulich, MD, St. Clair Shores, MI, present this QD Clinic: Tophi Tales: Management of Uncontrolled Gout. This QD Clinic is presented as part of RheumNow's "Mission: APP Partners in Care" https://t.co/7JTbC0223I
Dr. John Cush @RheumNow ( View Tweet)
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis
Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w
Dr. John Cush @RheumNow ( View Tweet)
2025 Rheumatologists, In Memorium
In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr. https://t.co/MMa670vsoH
Dr. John Cush @RheumNow ( View Tweet)
J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/KMseKyGirt
Dr. John Cush @RheumNow ( View Tweet)
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty.
Register: https://t.co/MVgXnacU5q https://t.co/7ajH7Ry0Uj
Links:
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Master the dos and don'ts of ordering RF, CCP (ACPA), and inflammatory markers that could transform your diagnostic accuracy.
Read Article
Podcasts
2026 Resolutions (1.9.2026)
DERM on RheumNow Podcast (December 2025)
Comorbidity and Health Management-
Telling You Where to Go (12.19.2025)
Therapeutic Updates
Advancing the Treatment Landscape for Pediatric Psoriatic Disease
Sponsored by Johnson & Johnson
Learn more about a treatment offering pediatric patients 6 years and older who also weigh at least 40 kg, and their physicians and adult caregivers, an option that may improve skin clearance for moderate to severe plaque psoriasis or treat active psoriatic arthritis, collectively known as psoriatic disease.
Read Post
Underserved and Under-treated
RheumNow
Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Pain Management and Workforce & APPs
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
